PCN6: MODELLING THE COST-EFFECTIVENESS OF DOCETAXEL IN THE SECOND LINE TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC)  by Sharplin, P et al.
Abstracts 433
PCN5
FIRST-LINE THERAPY FOR ADVANCED BREAST 
CANCER — COST-EFFECTIVENESS OF 
ANASTROZOLE VERSUS TAMOXIFEN
Marchetti M1, Liberato N2, Barosi G1
1IRCCS Policlinico San Matteo, Pavia, Italy; 2Civil Hospital, 
Voghera, Italy, Pavia, Italy
OBJECTIVE: New generation nonsteroidal aromatase
inhibitors are potent, selective and well-tolerated anti-
estrogens that improve survival of advanced breast can-
cer patients when used as second-line agents. Anastro-
zole, an aromatase inhibitor, was recently investigated as
first-line therapy. Its cost, however, is 10 times higher
than the cost of tamoxifen. Consequently the cost-effec-
tiveness of anastrozole is to be investigated.
METHODS: We first addressed the cost per month-with-
out-progression with a three-state Markov tree (response;
progression; withdrawal) with monthly transitions. The
probability of progression was obtained by pooling the
data from estrogen-positive women enrolled into the
three randomized clinical trials. The monthly rate of
withdrawal was assumed to be time-independent and the
cost of withdrawal was equivalent to the approximate
charge for a thromboembolic event. According to the
Italian market, the monthly cost of tamoxifen was $18
and that of anastrozole, $190. No other difference in
costs was assumed between the two treatments.
RESULTS: Since anastrozole allowed for a gain of 1.77 pro-
gression-free months, the resulting marginal cost-effective-
ness of anastrozole versus tamoxifen was $1395/month-
without-progression. We then calculated the lag time
from progression to death and considered the average
monthly cost of those patients who progressed while on
first-line therapy to be $1000. The cost-effectiveness of
anastrozole was thus $19,428/life year saved, and, after
adjustment for quality of life, $33,476/QALY. The re-
sults were not sensitive to an increase in drug cost of
30%, while they were sensitive to a variation in the rela-
tive risk of progression.
CONCLUSION: Anastrozole is a cost-effective second
line therapy for post-menopausal women with advanced
breast cancer and positive for estrogen receptors. It is
also a potentially cost-effective first-line hormonal ther-
apy. Both clinical and economic data are needed from
cross-over trials to confirm the cost-effectiveness in this
indication.
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OBJECTIVE: Until recently, best supportive care (BSC)
has been the only option for NSCLC patients who do not
respond to first line platinum based chemotherapy. Doce-
taxel was recently approved by NICE for use in patients
with locally advanced or metastatic lung cancer. This
study modeled the incremental cost-effectiveness of doce-
taxel and BSC versus BSC alone, in terms of direct
health-care costs per life year gained.
METHOD: The model used the results of a published
trial, which directly compared docetaxel plus BSC with
BSC alone. The difference in mean survival between the
docetaxel group and the BSC group was calculated as
3.82 months. Costs principally comprised drug acquisi-
tion and administration. In the reported trial result there
were no costs for toxicity treatment or any cost offsets,
because of incomplete trial data on non-chemotherapy
treatments. However, a worst case was modeled, includ-
ing possible toxicity treatment costs, and a best case, in-
cluding possible cost offsets. Sensitivity analysis also var-
ied months of life gained by taking the weighted average
of the worst two survival results (worst case) and the best
two survival results (best case) from four phase II trials.
Patient mean body mass and the number of vials used to
meet dose requirements were also varied.
RESULTS: The model estimated a cost per life year gained
of £13,618. (Best case £7,086; worst case £28,905). These
cost-effectiveness ratios compare favourably to accepted
standards in the UK. Whilst not captured in the model, the
published study showed no significant difference between
the docetaxel group and the BSC group in terms of quality
of life, but all QoL parameters favoured the docetaxel arm.
CONCLUSION: Docetaxel is a cost-effective treatment for
pre-treated NSCLC in terms of survival, with a non-signifi-
cant trend to improved quality of life compared to BSC.
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COST OF THE POST-PBPC REINFUSION
PERIOD IN HIGH DOSE TREATMENT OF
NON-HODGKIN’S FOLLICULAR LYMPHOMA 
(N-HFL) WITH AND WITHOUT FILGRASTIM
Van Kriekinge G1, Coiffier B2, Witz B3, Erder HM4, Standaert B1
1Amgen Inc, Brussels, Belgium; 2Centre Hospitalier Lyon Sud, 
Pierre Bénite, France; 3Hôpital Brabois, Vandoeuvre les Nancy, 
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OBJECTIVES: to retrospectively assess the cost of treat-
ment following reinfusion of PBPC after high-dose che-
motherapy in n-HFL patients until day 90 post-reinfusion
in an open-label, randomised phase III trial comparing
the treatment with and without filgrastim. The study was
a multi-centre trial conducted in France between 1995–
1999.
METHODS: Of fifty-one patients enrolled, 27 received
filgrastim (FI) and 24 were in the control arm (C). Demo-
graphic and disease-specific information was collected
through the CRF. Costs measured were hospital duration
(normal ward and ICU), drugs, transfusions, diagnostics
and lab tests. Drug prices were retrieved from the VIDAL
2000 database and on-line BIAM database. Costs of hos-
pitalization and technical procedures were obtained from
